Clinical Trials on Multiple System Atrophy in Australia

Total 6774 results

Daré Bioscience, Inc.

Completed

Study of Intravaginal Tamoxifen in PostMenopausal Women With VVA (DARE-VVA1)

Vulvar Atrophy

Australia
Daré Bioscience, Inc.

Completed

Study of DARE-HRT1 Over 12 Weeks in Healthy PostMenopausal Women (DARE-HRT1)

Vasomotor Symptoms | Vulvovaginal Atrophy

Australia
PYC Therapeutics

Not yet recruiting

Natural History of Autosomal Dominant Optic Atrophy (ADOA), Caused by OPA1 Mutation

Optic Atrophies, Hereditary | Autosomal Dominant Optic Atrophy | Optic Atrophy, Autosomal Dominant | Kjer Optic Atrophy

Australia
Royal Brisbane and Women's Hospital

Completed

Efficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple System Atrophy

Parkinson's Disease | Multiple System Atrophy | Orthostatic Hypotension

Australia
Universitätsklinik für Neurologie, Innsbruck

Recruiting

Abdominal Binders to Treat Orthostatic Hypotension in Parkinsonian Syndromes (ABOH-PS)

Parkinson Disease | Multiple System Atrophy, Parkinson Variant | Orthostatic; Hypotension, Neurogenic

Austria
Daré Bioscience, Inc.

Completed

A Phase 1, Open-Label, Parallel Group Study to Evaluate the Pharmacokinetics and Safety of DARE-HRT1 in Healthy PostMenopausal Women

Vasomotor Symptoms | Vulvovaginal Atrophy

Australia
AstraZeneca

Completed

AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients

Multiple System Atrophy, MSA

United States, Finland, Austria, France, Sweden, United Kingdom, Italy
Universitätsklinik für Neurologie, Innsbruck
Medical University Innsbruck; University of Erlangen-Nürnberg, Germany; University... and other collaborators

Recruiting

Mobility in Atypical Parkinsonism: a Trial of Physiotherapy (Mobility_APP)

Parkinson Disease | Progressive Supranuclear Palsy | Multiple System Atrophy, Parkinson Variant (Disorder)

Austria
Medical University Innsbruck

Recruiting

Medical Decision Making in Multiple System Atrophy (MeDeMSA)

Multiple System Atrophy

Austria
Madorra

Completed

Non-hormonal Medical Device for Treatment of Vulvovaginal Atrophy (VVA) in Post-Menopausal Women

Vulvovaginal Atrophy

Australia
Medical University of Vienna
Department of Surgery, Social Medical Centre South, Vienna, Austria; Institute...

Completed

Randomized, Controlled Study to Investigate the Effect of Neuromuscular Electrical Stimulation (NMES) on Muscle Metabolism of Abdominal Surgical Patients

Muscular Atrophy

Austria
German Parkinson Study Group (GPS)
Competence Network on Parkinson's Disease; European MSA-Study Group; Federal...

Completed

Study About Efficacy and Safety to Treat Multi-System-Atrophy

Multi-System-Atrophy | Minocycline

Austria, Germany
GlaxoSmithKline

Completed

Assessment of Repeat Ascending Doses of GSK2018682 in Healthy Volunteers (P1A114347)

Multiple Sclerosis, Relapsing-Remitting

Australia
Biogen

Completed

Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta (RENeu)

Relapsing-Remitting Multiple Sclerosis

New Zealand, Australia
Center for Eye Research Australia
AlphaRET Pty Ltd.

Recruiting

Subthreshold Laser Treatment in Intermediate Age-related Macular Degeneration With Nascent Geographic Atrophy Study (LIANA)

Age-Related Macular Degeneration

Australia
Innate Immunotherapeutics
Syneos Health

Completed

Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis

Secondary Progressive Multiple Sclerosis

New Zealand, Australia
Merck KGaA, Darmstadt, Germany
Merck Serono Australia Pty Ltd

Completed

Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting. (ReNew)

Multiple Sclerosis

Australia
Center for Eye Research Australia

Recruiting

Project AMD: Comprehensive Characterisation of Age-Related Macular Degeneration and Its Progression (Project AMD)

Age-related Macular Degeneration | Geographic Atrophy | Age Related Macular Degeneration | AMD

Australia
Medical University of Graz

Recruiting

Microbiome and Sarcopenia in Patients With Liver Cirrhosis

Liver Cirrhosis | Sarcopenia

Austria
Biogen

Terminated

How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full Dose (TODAY)

Relapsing Remitting Multiple Sclerosis

Australia
The Alfred

Completed

Acute Skeletal Muscle Wasting and Relation to Physical Function in Patients Requiring ECMO

Critical Illness | Extracorporeal Membrane Oxygenation | Muscle Wasting

Australia
Synchron Medical, Inc.

Withdrawn

SWITCH II Early Feasibility Study: Implantable BCI to Control a Digital Device for People With Paralysis

Paralysis | Amyotrophic Lateral Sclerosis | Muscular Dystrophies | Neurologic Disorder | Spinal Muscular Atrophy | Spinal Cord Injury | Stroke, Lacunar | Upper Limb Injury | Paralysis; Stroke | Stroke, Brainstem

Australia
Alterity Therapeutics

Recruiting

Study of ATH434 in Participants With Multiple System Atrophy

Multiple System Atrophy

United States, Australia, New Zealand, United Kingdom, Italy, France, Austria
GlaxoSmithKline

Completed

A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers. (P1A114919)

Multiple Sclerosis, Relapsing-Remitting

Australia
Hoffmann-La Roche

Active, not recruiting

A Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy (Rainbowfish)

Muscular Atrophy, Spinal

United States, Belgium, Brazil, Russian Federation, Australia, Taiwan, Poland
Pipeline Therapeutics, Inc.

Completed

Phase I Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of of PIPE-307 and Food Effect in Healthy Volunteers

Multiple Sclerosis

Australia
Ionis Pharmaceuticals, Inc.

Recruiting

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON) (HORIZON)

Multiple System Atrophy

Austria, Portugal, France, Germany, United Kingdom
GlaxoSmithKline

Completed

Healthy Volunteer Study Using 3 Different Formulations of Firategrast

Multiple Sclerosis, Relapsing-Remitting

Australia
Theravance Biopharma

Recruiting

Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy (CYPRESS)

MSA - Multiple System Atrophy | Symptomatic Neurogenic Orthostatic Hypotension

United States, Spain, United Kingdom, Hungary, Italy, Argentina, Austria, Poland, Germany, Portugal, Belgium, Brazil, Denmark, Estonia, Canada, France, Chile
Pfenex, Inc

Completed

Comparison Study of PF530 and Betaferon in Healthy Subjects

Multiple Sclerosis

Australia
GlaxoSmithKline

Completed

Healthy Volunteer Pilot Study Using 3 Types of Modified Release Formulations of Firategrast to Investigate How Quickly Absorption From the Digestive System Takes Place.

Multiple Sclerosis, Relapsing-Remitting

Australia
Novartis Pharmaceuticals

Completed

Mayzent (Siponimod) Onboarding of Secondary Progressive Multiple Sclerosis (SPMS) Patients With MSGo

Secondary Progressive Multiple Sclerosis

Australia
Novartis Pharmaceuticals

Completed

A Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD Patients (RIVAL)

Age-Related Macular Degeneration

Australia
Novartis Pharmaceuticals

Recruiting

Characterizing the Use of Ofatumumab in a Real World Setting (EAFToS)

Relapsing Multiple Sclerosis

Australia
Novartis Pharmaceuticals

Recruiting

Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials (SPECTRUM)

Spinal Muscular Atrophy (SMA)

Spain, Canada, Taiwan, Belgium, Japan, Italy, Singapore, United Kingdom, France, Australia, Denmark, United States
Novartis Gene Therapies
PRA Health Sciences

Completed

Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2 (SPR1NT)

Spinal Muscular Atrophy

United States, United Kingdom, Australia, Belgium, Canada, Japan
GlaxoSmithKline

Completed

GSK2018682 FTIH in Healthy Volunteers (P1A114070)

Multiple Sclerosis

Australia
Royal North Shore Hospital

Unknown

Laser Therapy for Vulvovaginal Symptoms in Breast Cancer Patients (LAAVA2)

Vulvovaginal Atrophy | Genitourinary Symptoms and Ill-Defined Conditions

Australia
Hoffmann-La Roche

Recruiting

A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy (MANATEE)

Spinal Muscular Atrophy (SMA)

Belgium, United States, Croatia, Japan, Netherlands, Spain, Canada, Poland, United Kingdom, Italy, Portugal, Australia
Australian Catholic University
Curtin University; Pendulum Therapeutics

Active, not recruiting

OsteoPreP: Food Supplements for Postmenopausal Bone Health (OsteoPreP)

Glucose Metabolism Disorders | Postmenopausal Osteopenia | Age-related Cognitive Decline | Age-Related Sarcopenia | Bone Loss, Age Related

Australia
Southern Adelaide Local Health Network

Active, not recruiting

Virtual Management of Lung Nodules

Pulmonary Nodule, Solitary | Pulmonary Nodule, Multiple

Australia
Novartis Pharmaceuticals

Completed

Time and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple Sclerosis (TIMIOS)

Relapsing Forms of Multiple Sclerosis

Australia, United States
Belite Bio, Inc

Recruiting

Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy (PHOENIX)

Geographic Atrophy

United States, Taiwan, Australia, China, United Kingdom
Medical University of Vienna

Recruiting

A Modified Sinus Floor Elevation Technique - a Pilot Study on 12 Patients

Atrophy | Maxillary Sinus

Austria
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA) (SMART)

Spinal Muscular Atrophy

Taiwan, Belgium, Canada, United States, Australia, France, Italy, Portugal, United Kingdom
ONL Therapeutics

Completed

ONL1204 Ophthalmic Solution in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration

Geographic Atrophy

New Zealand, Australia
Novartis Pharmaceuticals

Active, not recruiting

Phase IIIb, Open-label, Multi-center Study to Evaluate Safety, Tolerability and Efficacy of OAV101 Administered Intrathecally to Participants With SMA Who Discontinued Treatment With Nusinersen or Risdiplam (STRENGTH)

Spinal Muscular Atrophy

Japan, Belgium, Spain, Canada, United States, Australia, Italy, France, Netherlands
Ichnos Sciences SA

Not yet recruiting

Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

Australia
Novartis Gene Therapies

Active, not recruiting

Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi

SMA | Spinal Muscular Atrophy Type II | Spinal Muscular Atrophy Type I | Spinal Muscular Atrophy Type III

United States, Belgium, France, Japan, United Kingdom, Italy, Taiwan, Australia, Canada
Allergan

Completed

Safety and Efficacy of Brimonidine Intravitreal Implant in Patients With Geographic Atrophy Due to Age-related Macular Degeneration (AMD)

Macular Degeneration

Korea, Republic of, Australia, Portugal, Germany, United States, Philippines, Italy

Clinical Trials on Multiple System Atrophy in Australia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Peru

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations